Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and a member of the Board of Directors (the ?Board?) of Onconetix, Inc. (the ?Company?). Dr. Campbell?s resignation is not the result of any disagreement with the Company relating to the Company?s operations, policies or practices. Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board?s appointment of a permanent chief executive officer.

Mr. Sapirstein shall receive $40,000 per month as compensation for his services as Lead Independent Director.